Drug-induced liver injury with cholestasis. Part 2: focus on antidiabetic drugs
- Authors: Ostroumova O.D1, Pereverzev A.P1, Gusenbekova D.G1, Pavleeva E.E2
-
Affiliations:
- Russian Medical Academy of Continuous Professional Education
- A.I. Yevdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 27, No 14 (2020)
- Pages: 28-36
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313006
- DOI: https://doi.org/10.18565/pharmateca.2020.14.28-36
- ID: 313006
Cite item
Abstract
Full Text
About the authors
O. D Ostroumova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
A. P Pereverzev
Russian Medical Academy of Continuous Professional Education
Email: acchirurg@mail.ru
Cand. Sci. (Med.), Associate Professor, Department of Therapy and Polymorbid Pathology 2/1, build. 1, Barrikadnaya str., Moscow 125993, Russian Federation
D. G Gusenbekova
Russian Medical Academy of Continuous Professional EducationMoscow, Russia
E. E Pavleeva
A.I. Yevdokimov Moscow State University of Medicine and DentistryMoscow, Russia
References
- Omar H., Kolia J., Mangar D., Camporesi E. GUmepiride-induced cholestasis in a man with diabetes meiiitus: a case report. J Med Case Reports. 2009;3:9257. doi: 10.4076/1752- 1947-3-9257.
- Nammour F.E., Fayad N.F., Peikin S.R. Metformin-induced choiestatic hepatitis. Endocr Pract. 2003;9(4):307-9. doi: 10.4158/EP9.4.307.
- Desiiets D.J., Shorr A.F., Moran K.A., Hoitzmuiier K.C. Choiestatic jaundice associated with the use of metformin. Am J Gastroenteroi. 2001;96(7):2257-58. doi: 10.1111/j.1572-0241.2001.03972.x.
- Thoiakanahaiii V.N., Potti A., Heyworth M.F. Giibenciamide-induced choiestasis. West J Med. 1998;168(4):274-47.
- Dei-Vai A, Garrigues V, Ponce J., Benages R. Giibenciamide-induced choiestasis. J Hepatoi. 1991;13(3):375. doi: 10.1016/0168- 8278(91)90085-p.
- Kamai P, Bhabhra R. Giipizide Induced Hepatotoxicity: A Case Report and Review of Literature. J Diabetes Metab Disord 2019;6:028. doi: 10.24966/DMD-201X/100028.
- Pin to A.G., Cummings O.W., Chaiasani N. Severe but reversibie choiestatic iiver injury after piogiitazone therapy. Ann Intern Med. 2002;137(10):857. doi: 10.7326/0003-4819-137-10-200211190-00023.
- Bonkovsky H.L., Azar R., Bird S, et ai. Severe choiestatic hepatitis caused by thiazoiidinediones: risks associated with substituting rosigiitazone for trogiitazone. Dig Dis Sci. 2002;47(7):1632-37. doi: 10.1023/a:1015895925374.
- Tisdaie J.E., Miiier D.A. Drug-Induced Diseases: Prevention, Detection, and Management. Am J Pharm Educ. 3rd ed. 2018.
- Kapiowitz N, DeLeve L.D, eds. Drug-induced iiver disease. 3rd ed. Amsterdam: Eisevier, 2013. Doi: https://doi.org/10.1016/C2010-0-68917-6.
- Kutoh E. Possibiemetformin-inducedhepatotoxicity. Am J Geriatr Pharmacother. 2005;3(4):270-73.
- Saadi T, Waterman M, Yassin H, Baruch Y. Metformin-induced mixed hepatoceiiuiar and choiestatic hepatic injury: case report and iiterature review. Int J Gen Med. 2013;6:703-706. doi: 10.2147/IJGM.S49657
- Barquero Romero J., Perez Miranda M. Hepatitis coiestasica inducida por meftormina [Metformin-induced choiestatic hepatitis]. Gastroenteroi Hepatoi. 2005;28(4):257-58. doi: 10.1157/130 7309 7.
- Gupta R., Sachar D.B. Chiorpropamide-induced choiestatic jaundice and pseudomembranous coiitis. Am J Gastroenteroi. 1985;80(5):381-83.
- Rumboidt Z., Bota B. Favorabie effects of giibenciamide in a patient exhibiting idiosyncratic hepatotoxic reactions to both chiorpropamide and toibutamide. Acta Diabetoi Lat. 1984;21(4):387-91. doi: 10.1007/BF02582093.
- Wongpaitoon V., Miiis P.R., Russeii R.I., Patrick R.S. Intrahepatic choiestasis and cutaneous buiiae associated with giibenciamide therapy. Postgrad Med J. 1981 ;57(666):244-46. doi:10.1136/ pgmj.57.666.244.
- May L.D., Lefkowitch J.H., Kram M.T., Rubin D.E. Mixed hepatoceiiuiar-choiestatic iiver injury after piogiitazone therapy. Ann Intern Med. 2002;136(6):449-52. doi: 10.7326/0003-4819-136-6-200203190-00008.
- Fioyd J.S., Barbehenn E., Lurie P, Woife S.M. Case series of liver failure associated with rosiglitazone and pioglitazone. Pharmacoepidemiol Drug Saf. 2009;18(12):1238-1243. doi: 10.1002/ pds.1804.
- Ерёмина Е.Ю. Лекарственные поражения печени. Гастроэнтерология Санкт-Петербурга. 2012;(1):16-23.
- Садовникова И.В., Садовникова В.В. Клиникоэкспериментальное обоснование урсосанотерапии при токсическом медикаментозном гепатите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007;17(1):69
- Sundaram V, Bjornsson E.S. Drug-induced cholestasis. Hepatol Commun. 2017;1(8):726-35. doi: 10.1002/hep4.1088.
- Лазебник Л.Б., Звенигородская Л.А., Хомерики С.Г. и др. Лекарственный (статиновый) гепатит. Экспериментальная и клиническая и гастроэнтерология. 2009;(3): 110-16.
- Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю. и др. Изучение влияния урсодезоксихолевой кислоты на эффективность и безопасность лечения статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей (исследование РАКУРС). Рациональная фармакотерапия в кардиологии. 2014;(10)2:147-52.
- Ивашкин В.Т, Жаркова М.С., Маевская М.В., Лапшин А.В. Случай тяжелого лекарственного гепатита, индуцированного длительным приемом кордарона. Российские медицинские вести. 2009;(2):78-83
- Сивякова О.Н., Шманова Н.Ю., Дулеба А.П. Случай множественных побочных эффектов амиодарона. Consilium Medicum. 2018;20(5):71-74. doi: 10.26442/2075-1753_2018.5.71-74
- Киякбаев Г.К. Аритмии сердца. Основы электрофизиологии, диагностика, лечение и современные рекомендации. Под. ред. В.С. Моисеева. М.: ГЭОТАР-Медиа, 2014
- Государственный реестр лекарственных средств Минздрава России. URL: http://grls. rosminzdrav.ru. (дата обращения/date of access: 10.07.2020).
- Официальный сайт международной базы данных нежелательных реакций ВОЗ VigiAccess. [The official site of the international database of adverse reactions WHO VigiAccess. (In Russ.)]. Available at: http://www.vigiaccess.org (дата обращения/date of access: 10.07.2020).
- Ratz Bravo A.E., Drewe J., Schlienger R.G., et al. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med. 2005;33(1):128-46. doi: 10.1097/01. ccm.0000151048.72393.44.
- Giannattasio F., Salvio A., Varriale M., et al. Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity. Ann Ital Med Int. 2002;17(3):180-84.
- Rhodes A., Eastwood J.B., Smith S.A. Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? Gut. 1993;34(4):565-66. doi: 10.1136/gut.34.4.565.
- James P.R., Hardman S.M. Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy. Heart. 1997;77(6):583-84. doi:10.1136/ hrt.77.6.583.
- Kicker J.S., Haizlip J.A., Buck M.L. Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant. J Pediatr Pharmacol Ther. 2012;17(2):189-95. doi: 10.5863/1551-6776-17.2.189.
- Nasser M., Larsen T.R., Waanbah B., et al. Hyperacute drug-induced hepatitis with intravenous amiodarone: case report and review of the literature. Drug Healthc Patient Saf. 2013;5:191-98. doi: 10.2147/DHPS.S48640.
- Vassallo P, Trohman R.G. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312-1322. doi: 10.1001/jama.298.11.1312.
- Heger J.J., Prystowsky E.N., Jackman W.M., et al. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med. 1981;305(10):539-45. doi:10.1056/ NEJM198109033051002.
- Lewis J.H., Ranard R.C., Caruso A., et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989;9(5):679-85. doi: 10.1002/ hep.1840090504.
- Mattar W., Juliar B., Gradus-Pizlo I., Kwo P.Y. Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure. J Gastrointestin Liver Dis. 2009;18(4):419-23.
- Llanos L., Moreu R., Peiro A.M., et al. Causality assessment of liver injury after chronic oral amiodarone intake. Pharmacoepidemiol Drug Saf. 2009;18(4):291-300. doi: 10.1002/pds.1709.
- Переверзев А.П., Остроумова О.Д. Лекарственно-ассоциированная жировая болезнь печени. Безопасность и риск фармакотерапии. 2020;(2):8:66-76. [
- Pendyala V.S. A Case of Amiodarone-induced Hepatitis and Review of the Literature J Hepatol Gastroint Dis. 2016;2(1):1-3. doi: 10.4172/2475-3181.1000120.
- Hussain N., Bhattacharyya A., Prueksaritanond S. Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN Cardiol. 2013;2013:617943. doi: 10.1155/2013/617943.
- Chang C.C., Petrelli M., Tomashefski J.F. Jr, McCullough A.J. Severe intrahepatic cholestasis caused by amiodarone toxicity after withdrawal of the drug: a case report and review of the literature. Arch Pathol Lab Med. 1999;123(3):251-56. doi: 10.1043/0003-9985(1999)123<0251:SICC BA>2.0.CO;2.
- Rabinowich L., Shibolet O. Drug Induced Steatohepatitis:An Uncommon CulpritofaCommon Disease. Biomed Res Int. 2015;2015:168905. doi: 10.1155/2015/168905.
- Nemati M.H., Astaneh B. Amiodarone Versus Propafenone to Treat Atrial Fibrillation after Coronary Artery Bypass Grafting: A Randomized Double Blind Controlled Trial. Korean J Thorac Cardiovasc Surg. 2016;49(3):1 77-84. doi: 10.5090/kjtcs.2016.49.3.177.
- Петрова В.Б., Петрова А.И., Лаптева Е.С. Парентеральное введение лекарственных веществ. Внутривенная капельная инфузия. Взятие венозной крови. Постинъекционные осложнения. (Часть 2). Учебно-методическое пособие. СПб.: Изд-во СЗГМУ им. И.И. Мечникова, 2013. 44 с.
- Treglia A., Alfano C., Rossini E. Confronto tra propafenone ed amiodarone nella conversione al. ritmo sinusale della fibrillazione atriale di recente insorgenza [A comparison between propafenone and amiodarone in the conversion to sinus rhythm of atrial fibrillation of recent onset]. Minerva Cardioangiol. 1994;42(6):293-97.
- Yi-Shin Huang. The Therapeutic Efficacy of Ursodeoxy-cholic Acid (UDCA) in Drug-induced Liver injury: Results of a Randomized Controlled Trial. Available at: https://www. gastrojournal.org/ article/S0016-5085(10)63727-4/pdf. (date of access: 10.07.2020).
- Wree A., Dechne A., Herzer K., et al. Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. Digestion. 2011;84(1):54-59. doi: 10.1159/ 000322298.
- Lang S.M., Ortmann J., Rostig S., Schiffl H. Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. int J Mycobacteriol. 20 19;8( 1 ):89-92. doi: 10.4103/ijmy. ijmy_159_18.
- FAN Shu-bing, FAN Shu-qi. Effect of ursodeoxycholic on drug-induced liver injury. Available at: http://en.cnki.com.cn/Article_en/ CJFDTotal-JLYX201129026.htm (date of access: 06.07.2020).
- Ивашкин В.Т, Барановский А.Ю., Райхельсон К.Л. и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):101-131. Doi: https://doi.org/10.22416/1382-4376-2019-29-1-101-131.
- Mohankumar N., Ranjan P, Kumari A. Drug-induced liver injury: Diagnosing (and treating) it early. J Fam Pract. 2015;64(10):634-44.
- Devarbhavi H. An Update on Drug-induced Liver injury J Clin Exp Hepatol. 2012;2(3):247-59. doi: 10.1016/j.jceh.2012.05.002.
- de Caestecker J.S., Jazrawi R.P., Petroni M.L., Northfield T.C. Ursodeoxycholic acid in chronic liver disease. Gut. 1991;32(9): 1061-1065. doi:10.1136/ gut.32.9.1061
- Ивашкин В.Т., Широкова Е.Н., Маевская М.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015;(2):41-57.
- Лазебник Л.Б., Голованова Е.В., Хлынова О.В. и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;2(174):29-54. doi: 10.31146/1682-8658-ecg-174-2-2954
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237-267. doi: 10.1016/j. jhep.2009.04.009.
- Nathwani R.A., Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis. 2006;10(2):207-vii. doi: 10.1016/j. cld.2006.05.009.
- Liu L.W., Zhao X.Y., Jia J.D. [EASL clinical practice guidelines recommendations for drug-induced liver injury in 2019]. Zhonghua Gan Zang Bing Za Zhi. 2019 Jun 20;27(6):420-423. Chinese. doi: 10.3760/cma.j.issn.1007-3418.2019.06.006.
- European Association for the Study of the Liver. Clinical Practice Guideline Panel: Chair; Panel members; EASL Governing Board representative. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222-1261. doi: 10.1016/j.jhep.2019.02.014.
- LiverTox® - ресурс для специалистов практического здравоохранения по вопросам лекарственнного поражения печени. URL: https://iivert.ox.nih.gov/ Phenotypes_iact.htmi (дата обращения/date of access: 16.05.2020)